摘要
目的考察水飞蓟宾对艾滋病合并肝炎治疗的辅助疗效。方法收集2010年5月～2011年6月在我院住院治疗的艾滋病合并丙型肝炎病患75例,随机分为两组,治疗组39例,水飞蓟宾组36例。结果两组治疗前病毒载量、CD4+、CD8+、NK、肝功能和血脂在治疗前无显著差异(P>0.05)。与治疗前比,两组病毒载量、CD4+、CD8+和NK均有不同程度的改善(P<0.05),但两组之间无显著差异(P>0.05),对照组肝纤维化程度和血脂无显著差异(P>0.05),水飞蓟宾组的肝功能指标显著改善,肝纤维化程度较低(P<0.05),血脂指标显著改善(P<0.05)。结论水飞蓟宾可改善长效聚乙二醇化干扰素(PEG-IFNa-2a)治疗艾滋病合并肝炎治疗的疗效,尤其可改善肝功能,减少肝纤维化程度和血脂水平。
Objective To investigate the effect of silibinin in treatment of AIDS with hepatitis C patients. Methods From May 2010 to June 2011, 75 cases of AIDS with hepatitis C patients in our hospital were randomly divided into two groups： 39 cases of control group and 36 cases of silihinin treatment group. Results Before treatment, compare with control, viral load, CD4＋, CD8＋, NK, liver function and blood lipids silibinin group had no significant differences （P〉 0.05）. Compared with before treatment, viral load, CD4＋, CD8＋ and NK in 2 groups had improved （P 〈0.05）. But there was no significant differences in viral load, CD4＋, CD8＋ , NK between 2 groups （P〉0.05）. Compared with before treatment, liver fibrosis degree and lipids in control group had no significant differences （P〉0.05）, hut liver function, liver fibrosis and lipid in silibinin group had significantly improved （P〈0.05）. Conclusion Silibinin can improve liver function, reduce liver fibrosis and lipid levels in AIDS with hepatitis C by improving the effect of PEG-IFNa-2a.
出处
《中国现代医生》
2014年第2期45-47,50,共4页
China Modern Doctor
基金
浙江省医学会临床科研基金(2011ZYC-A70)
